TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02671500
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily
Study: NCT03568643
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
Study: NCT01459887
Drug: CHOP, CMAB304
Approvals — FDA: no, EMA: no, PMDA: no
Description: First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
Study: NCT02626455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
Study: NCT02626455
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study: NCT02626455
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
Study: NCT02240589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
Study: NCT00558792
Drug: Isovue 370, 80 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
Study: NCT00558792
Drug: Isovue 370, 90 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
Study: NCT00023998
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00023998
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00023998
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT03006640
Drug: Subcutaneous nitroglycrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
Study: NCT03006640
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
Study: NCT01499563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing inactive placebo for 28 days
Study: NCT01825798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
Study: NCT01395069
Drug: Nepafenac 0.1%
Normalized name: NEPAFENAC 0.1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop QID for 1 month
Study: NCT00873262
Drug: Skin test panel and solvent
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
Study: NCT01606371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01606371
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02473965
Drug: IGIV-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks
Study: NCT02473965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01240551
Drug: F-18 NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
Study: NCT00078377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets once daily
Study: NCT03554408
Drug: 3BNC117-LS
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 3BNC117-LS
Study: NCT03554408
Drug: 3BNC117-LS
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3BNC117-LS
Study: NCT00132678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo intramuscular (IM) injection every 2 weeks
Study: NCT01395043
Drug: Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
Study: NCT01727492
Drug: Antioxidantia
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00883103
Drug: Plain aqueous gel
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
Study: NCT01677780
Drug: RO5045337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
Study: NCT03608059
Drug: ATG/PTCy
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
Study: NCT03608059
Drug: standard ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
Study: NCT01234883
Drug: multiple electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV multiple electrolyte solution dosed as clinically indicated for rehydration
Study: NCT02813902
Drug: Heliocare with Fernblock PLE technology
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg taken orally daily over the course of 1 year
Study: NCT04076462
Drug: CAM2029 (octreotide subcutaneous depot)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide subcutaneous depot for monthly injections in acromegaly patients
Study: NCT04076462
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for CAM2029
Study: NCT04283539
Drug: systemic corticosteroid or biologic
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)
Study: NCT04901923
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive ACP-196 oral capsule(s) in all parts.
Study: NCT00111995
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01037959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill/day (per os) for 6 months
Study: NCT01219803
Drug: Mild dose GGQL Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
Study: NCT01250925
Drug: ReNu MultiPlus® MultiPurpose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact lens care regimen
Study: NCT01219803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
Study: NCT01758861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03664739
Drug: IDp-120 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-120 Vehicle Gel, once-daily application
Study: NCT00967174
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
Study: NCT02345590
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg of eplerenone
Study: NCT00474175
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose (less than 1g) of a matching placebo gel
Study: NCT03055962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT02777437
Drug: XELOX or FOLFOX chemotherapy
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
Study: NCT00474175
Drug: benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose (less than 1g) of 10% benzocaine gel formulation
Study: NCT00474175
Drug: benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose (less than 1g) of 20% benzocaine gel formulation
Study: NCT04537897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04942860
Drug: 1% Methotrexate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% methotrexate gel applied onto a predefined limb
Study: NCT04942860
Drug: 0.5% Methotrexate gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% methotrexate gel applied onto a predefined limb
Study: NCT01939353
Drug: CTN SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTN SR tablets
Study: NCT01939353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTN SR-matching placebo tablets
Study: NCT03173781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication
Study: NCT03160846
Drug: Inotrope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
Study: NCT02328079
Drug: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
Study: NCT01914770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
Study: NCT02838992
Drug: Cy
Normalized name: CYT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
Study: NCT00292422
Drug: BG9924
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01240915
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once every 7 days for 1- 3 doses
Study: NCT01240915
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose at week 8
Study: NCT01240915
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose Day 1
Study: NCT01375998
Drug: EE20/DRSP(YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in daily life treatment receiving YAZ for dysmenorrhea.
Study: NCT01735175
Drug: Neulasta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Study: NCT00466258
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cyclophosphamide 750 mg/m2 i.v. day 1~* Adriamycin 50 mg/m2 i.v. day 1~* Vincristine 1,4 mg/m2 i.v. day 1~* Prednisone 100 mg i.v or oral. days 1-5.
Study: NCT00466258
Drug: Central nervous system (CNS) prophylaxis
Normalized name: Syzygium nervosum flower bud extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
Study: NCT04562103
Drug: Epinephrine / Ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
Study: NCT01049438
Drug: oral anti-MRSA antibiotic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
Study: NCT02813044
Drug: total intravenous anesthesia (TIVA)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
Study: NCT02813044
Drug: inhalation anesthesia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
Study: NCT04192110
Drug: Diuretic initiation or augmentation
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
Study: NCT02567708
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
Study: NCT02605382
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
Study: NCT03901469
Drug: ZEN003694
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO QD
Study: NCT00798252
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
Study: NCT00798252
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
Study: NCT00879775
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
Study: NCT02226172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
Study: NCT00879775
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
Study: NCT02614183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03392168
Drug: ARQ-151 cream 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% active concentration
Study: NCT03392168
Drug: ARQ-151 vehicle cream
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream
Study: NCT04001647
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
Study: NCT04001647
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
Study: NCT00000331
Drug: Test Drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000331
Drug: Placebo Drug
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02148393
Drug: Pregnyl®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 IU
Study: NCT02148393
Drug: Utrogestan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tid
Study: NCT02148393
Drug: Progynova®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg bid
Study: NCT00502996
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: \>=15 mg po/week
Study: NCT00003944
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00867295
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02500979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by separate pump
Study: NCT02500979
Drug: Lispro insulin U-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
Study: NCT02500979
Drug: Regular insulin U-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
Study: NCT01347853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal post-surgery for up to 5 days total
Study: NCT00763490
Drug: Flu/Bu4 conditioning regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2
Study: NCT00763490
Drug: Graft versus Host Disease prevention (GVHD prophylaxis)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
Study: NCT00267111
Drug: Eucerin plus
Normalized name: Eucerin Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g, single application
Study: NCT00267111
Drug: Amethocaine gel 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g, single application
Study: NCT00439179
Drug: cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gem + GW572016, 1500 mg/day (combination)
Study: NCT00439179
Drug: cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX + GW572016 1000 mg/day (combination)
Study: NCT00439179
Drug: cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX + GW572016 1500 mg/day (combination)